NXERA PHARMA CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,458 JPY | -2.47% |
|
+0.55% | +2.60% |
ETFs positioned on Nxera Pharma Co., Ltd.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 7.92% | 24 M€ | -14.52% | ||
| 1.17% | 16 M€ | -8.49% | ||
| 0.55% | 15 M€ | +7.34% | ||
| 0.03% | 20,721 M€ | +13.52% | - | |
| 0.03% | 144,586 M€ | +14.49% | ||
| 0.03% | 66,066 M€ | +14.68% | - | |
| 0.02% | 773 M€ | -.--% | - | |
| 0.00% | 10 M€ | -3.35% | - |
Nxera Pharma Co Ltd, formerly known as Sosei Group Corp, is a Japan-based company engaged in the biopharmaceutical business that handles from drug research (drug discovery) to development and sale. The Company is mainly engaged in the pharmaceutical business. The Company is engaged in drug discovery, translational medicine, preclinical and early clinical development, as well as the research and development, import/export, packaging, and sale of pharmaceuticals. The Company also conducts structural analysis of G protein-coupled receptors (GPCRs), creates initial lead compounds, and searches for candidate products using StaR technology.
Sector
Pharmaceuticals
Calendar
2024-05-08
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
1,458
JPY
Average target price
2,100
JPY
Spread / Average Target
+44.03%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +2.60% | 828M | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| -9.14% | 11.95B | |
| +5.24% | 8.71B | |
| -8.42% | 8.12B |
- Stock Market
- Equities
- 4565 Stock
- Funds and ETFs Nxera Pharma Co., Ltd.
